I think you are right. However, what does that mean for Genta at the end of June? Will they go BK with this pipeline and trial stage just because of BOD failsures in the past?
The market need new drugs and Genta has some stuff. I'm not sure about it, but a take over/buy out etc. might be a solution.
the question at the end will be what happens to us share holders?